Regeneron Pharmaceuticals Inc. closed 44.49% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

Regeneron Pharmaceuticals Inc. closed 45.10% below its 52-week high of $1,211.20, which the company reached on August 27th.

The Dermatology Foundation (DF) and the Skin of Color Society (SOCS) announce that Crystal U. Aguh, MD, FAAD, is the 2025 ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

Jim Cramer said in response to a question during a recent program on CNBC that he’d recommend investors own Regeneron ...

Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...

The teen is the first student from Levittown's General Douglas MacArthur High School to be named a finalist in the ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...